71 related articles for article (PubMed ID: 24099070)
1. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
[TBL] [Abstract][Full Text] [Related]
2. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract][Full Text] [Related]
3. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE
ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238
[TBL] [Abstract][Full Text] [Related]
4. CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy.
Tanigawa A; Fukumoto T; Imamura S; Nakamura K; Tanaka T; Itoh T; Nakano E; Nishigori C; Kubo A
J Dermatol; 2023 Jul; 50(7):e210-e212. PubMed ID: 36740368
[No Abstract] [Full Text] [Related]
5. Chronic Radiation Dermatitis Secondary to Narrow-Band Ultraviolet B Therapy in a Patient With Primary Cutaneous CD8 + T-Cell Lymphoma With Cytotoxic Granules.
Edelson MP; Gay JJ; Thiel RW; Grider DJ
Am J Dermatopathol; 2024 May; 46(5):312-315. PubMed ID: 38513130
[TBL] [Abstract][Full Text] [Related]
6. Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.
Rosenthal J; Belfort G; Isaacson D
PLoS One; 2016; 11(4):e0153150. PubMed ID: 27073866
[TBL] [Abstract][Full Text] [Related]
7. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas.
Ta VA; Battistella M; Zhao LP; Dobos G; Ram-Wolff C; Madelaine I; Bories JC; Tournilhac O; Rouanet J; Veyrat-Masson R; Bouaziz JD; Marie-Cardine A; Bagot M; Bensussan A; Moins-Teisserenc H; De Masson A
J Invest Dermatol; 2023 Jul; 143(7):1329-1332.e3. PubMed ID: 36716922
[No Abstract] [Full Text] [Related]
8. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.
Giustiniani J; Dobos G; Moins-Teisserenc H; Eustaquio T; Battistella M; Ortonne N; Ram-Wolff C; Bouaziz JD; Marie-Cardine A; Mourah S; Bagot M; Kupper TS; Clark RA; Bensussan A; de Masson A
Blood Adv; 2022 Jun; 6(11):3507-3512. PubMed ID: 35201316
[No Abstract] [Full Text] [Related]
9. Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer.
Leal AS; Hung PY; Chowdhury AS; Liby KT
Pharmacol Ther; 2023 Dec; 252():108561. PubMed ID: 37952906
[TBL] [Abstract][Full Text] [Related]
10. Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations.
Milosheska D; Roškar R
Adv Ther; 2022 Dec; 39(12):5351-5375. PubMed ID: 36220974
[TBL] [Abstract][Full Text] [Related]
11. Trifarotene: A Current Review and Perspectives in Dermatology.
Cosio T; Di Prete M; Gaziano R; Lanna C; Orlandi A; Di Francesco P; Bianchi L; Campione E
Biomedicines; 2021 Feb; 9(3):. PubMed ID: 33652835
[TBL] [Abstract][Full Text] [Related]
12. Skin Directed Therapy in Cutaneous T-Cell Lymphoma.
Tarabadkar ES; Shinohara MM
Front Oncol; 2019; 9():260. PubMed ID: 31032224
[TBL] [Abstract][Full Text] [Related]
13. Targeting truncated RXRα for cancer therapy.
Zhang X; Zhou H; Su Y
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):49-59. PubMed ID: 26494413
[TBL] [Abstract][Full Text] [Related]
14. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J; Vacchelli E; Aranda F; Castoldi F; Eggermont A; Cremer I; Sautès-Fridman C; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 Apr; 4(4):e1008866. PubMed ID: 26137404
[TBL] [Abstract][Full Text] [Related]
15. Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins.
Doldo E; Costanza G; Agostinelli S; Tarquini C; Ferlosio A; Arcuri G; Passeri D; Scioli MG; Orlandi A
Biomed Res Int; 2015; 2015():624627. PubMed ID: 25879031
[TBL] [Abstract][Full Text] [Related]
16. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
17. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
[TBL] [Abstract][Full Text] [Related]
18. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
